Testing and Reporting Contrast Sensitivity

Mark Packer, MD, Arthur P. Ginsburg, PhD, MSEE

REPLY: Testing and Reporting Contrast Sensitivity

César Albarrán-Diego, MD, Gonzalo Muñoz, MD, PhD, FEBO
Testing and reporting contrast sensitivity

In their recent article about the Tecnis intraocular lens (IOL), Munoz et al.\textsuperscript{1} report elimination of the spherical aberration ($-0.0321 \pm 0.2856 \mu m$ for the Tecnis IOL versus $0.1511 \pm 0.1709 \mu m$ for the AR40e IOL and $0.2115 \pm 0.2131 \mu m$ for the Stabibag IOL) that is consistent with results in previous publications, which have shown that implantation of a modified prolate IOL with $-0.27 \mu m$ of spherical aberration produces a mean total ocular spherical aberration equivalent to zero. The authors also found that eyes with the Tecnis Z9000 had a greater Strehl ratio after surgery. However, they did not find a significant difference in contrast sensitivity between eyes implanted with the Tecnis Z9000 and fellow eyes implanted with either control IOL. The absence of a significant difference in contrast sensitivity at any spatial frequency runs counter to previous reports comparing the Tecnis Z9000 IOL and the AR40e\textsuperscript{2,3} as well as reports comparing the Tecnis with a variety of other spherical IOLs.\textsuperscript{4-6} The findings also directly contradict one publication that demonstrates significantly better visual acuity and better (although not statistically significantly better) contrast sensitivity\textsuperscript{7} and indirectly contradicts the findings of another report that shows significantly better contrast acuity following mydriasis.\textsuperscript{8}

Munoz et al.\textsuperscript{1} suggest several possible explanations for their findings, including IOL material, chromatic aberration, and IOL decentration (although they admit that their finding of reduced coma in the eyes implanted with the Tecnis IOL provides evidence against decentration). However, we were surprised they did not mention that the values they show for normalized contrast sensitivity in all eyes are abnormally low under both photopic and mesopic conditions.

We are concerned that the normalized contrast sensitivity values reported in this article are lower than expected for all tests, including the Z9000, AR40e, and Stabibag IOL eyes. In a previous publication by some of the same authors,\textsuperscript{9} normalized contrast sensitivity values in pseudophakic patients with spherical monofocal and multifocal IOLs were close to 1.0 at all spatial frequencies by 3 months postoperatively (Figure 1). It has also been demonstrated that the contrast sensitivity in pseudophakic patients implanted with spherical IOLs is the same as that in age-matched controls without cataract, and thus the pseudophakic eyes would be expected to have normalized contrast sensitivity approximating 1.0.\textsuperscript{10} The significantly lower values for contrast sensitivity reported in this paper suggest the possibility of an error in testing conditions, protocol, data management, or analysis.

One test condition that could create lower contrast sensitivity in the current study compared with that in the previous publication\textsuperscript{15} is the different contrast sensitivity testing systems used. The earlier publication used the FACT (Functional Acuity Contrast Test, Vision Sciences Research Corp.) and the present study used the VectorVision test system. The VectorVision contrast sensitivity system is less sensitive than the FACT system.\textsuperscript{15} Compared with the FACT grating system, the VectorVision gratings change contrast with changes in room illuminance; the white grating surround creates a glare source and the grating patches are considerably smaller than the FACT gratings. An in-house study of 20 normal subjects (mean age 37 years [range 26 to 51 years]) with a best corrected visual acuity of 20/20 compared the contrast sensitivity of FACT and VectorVision at 6 and 12 cycles per degree (cpd) under photopic test conditions (unpublished data). Under normal test conditions, the contrast sensitivity of FACT was slightly, but not significantly, higher. However, under glare (BAT on medium) and low contrast (homogeneous light scatter material), the FACT was twice as sensitive in measuring contrast loss as the VectorVision at 6 and 12 cpd. The relative insensitivity of the VectorVision test for loss of contrast sensitivity also means the VectorVision is a relatively insensitive measure of contrast gains such as those reported previously with the Tecnis IOL and the FACT system.\textsuperscript{6}

The differences in sensitivity to contrast between contrast test systems also cautions interpretation of

![Figure 1. The normalized contrast sensitivity reported in a previous publication\textsuperscript{1} for a spherical monofocal IOL (open squares) and a multifocal IOL (solid squares) at 0 cpd. The values are close to 1.0 for the spherical monofocal at all timepoints, whereas the values in the current publication vary from 0.6 (mesopic) to 0.8 (photopic). Reprinted with permission from Elsevier.](image)
normalized test results such as that given by Boxer-
Wachler and Krueger. 18 Two quite different contrast
sensitivity values can give similar normalized values,
masking significant changes in contrast sensitivity.
For example, one contrast sensitivity test system hav-
ing a normalized value of 0.8 for contrast sensitivity
values of 100 and 80 may find the 80 below the normal
population curve. However, another contrast sensitiv-
ity test system having a normalized value of 0.8 for
contrast sensitivity values of 150 and 120 may find
the 120 value within the normal population curve.
Normalization only works for similar contrast test
systems.

Measuring and reporting contrast sensitivity re-
 mains unfamiliar territory for most cataract and refrac-
tive surgeons. Variations in results should be
elicited with reference to differences in testing sys-
tems, procedures, and data analysis.

Mark Packer, MD
Eugene, Oregon, USA

Arthur P. Ginsburg, PhD, MSEE
San Ramon, California, USA

REFERENCES

REPLY: We appreciate this interesting letter discuss-
ing our paper about contrast sensitivity after cataract surgery with the Tecnis intraocular lens (IOL). In our paper, we found a statistically significant reduction of spherical aberration in patients implanted with the Tecnis IOL that was not associated with an improve-
ment in visual acuity or contrast sensitivity at photopic or mesopic illumination levels.

Previous studies have found a reduction in spheral aberration accompanied by an improvement in visual acuity and contrast sensitivity. However, it must be real-
ized that a statistically insignificant difference should not be considered an actual difference. Regarding testing under mydriasis, no comparison can be made with our paper’s results since we did not take contrast sensitivity measurements under this condition.

There are also reports of better contrast sensitivity at some spatial frequencies with the aspheric Tecnis IOL than with nonprolate IOLs. In these studies, the FACT chart was used to measure contrast sensitivity. It seems to be superior to the CSV1000E for measuring contrast sensitivity. However, we used the CSV1000E chart since at the time of our study, it was the only test available to us. We now have doubts about the sensi-
tivity of CSV1000E measurements at mesopic levels because the test itself is a source of illumination, making the actual retinal illumination level difficult to control, and the test itself can create an important glare source. For these reasons, we now prefer the FACT chart for contrast sensitivity measurements.

We also believe that one limitation of our study is the population size, as stated in the discussion of the paper. We measured contrast sensitivity in 30 eyes of
30 patients with the Tecnis IOL. Packer et al. found an improvement in contrast sensitivity after Tecnis IOL implantation in 10 patients in one study and in 15 patients in the other. The small sample size of these studies also make them weak in terms of statistical analysis. We believe that more investigation is needed with larger sample sizes to better understand the actual performance of aspheric IOLs and the effects on contrast sensitivity, especially at low illumination levels.

Our study is not the only one that discovered a reduction in spherical aberration with no increase in contrast sensitivity after prolate IOL implantation. Franchini proposed chromatic aberration as the reason that patients implanted with prolate lenses do not experience all the expected advantages. In an optical system such as the eye, compounded by several elements, the most restrictive element would mark the restriction of the entire system. So an improvement in one element would not mean an improvement in the whole system's performance.

We measured contrast sensitivity following the CSV100E manual indications for testing distance and illumination conditions, and we statistically evaluated the data obtained as recommended by VectorVision. There are several possible explanations for the disagreement between the contrast sensitivity values of Montes-Micó and Alió and our results. The mean age in the study by Montes-Micó and Alió was 64.9 ± 4.1 years in the multifocal group, whereas the mean age in our study was 74.8 ± 6.5 years, more than 10 years older. This could indicate that the normal scores would not be applicable to an older population. Another possible reason is the different charts used to measure contrast sensitivity. As pointed out by the authors of the letter, normalized values cannot be compared when contrast sensitivity testing has been done with different charts.

Finally, we would like to point out the importance of differentiating between the concepts of visual quality and optical quality. Good optical quality is mandatory for good visual quality, but an improvement in optical quality, such as that achieved with a prolate IOL, will not necessarily be translated into better visual quality. This fact has been demonstrated by Artal et al. in studies of ocular aberrations.—César Albarrán-Diego, MD, Gonzalo Muñoz, MD, PhD, FEBO

REFERENCES